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ABSTRACT

The discovery of checkpoint molecules blocking the immune system response
against cancer cells has been a great advancement in the field of immuneoncology. Antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and programmed death-ligand 1 (PD-1) and its ligand (PD-L1) have been
approved by the FDA for clinical use. Interestingly, ipilimumab, blocks CTLA-4
resulting in activated T cell signaling and enhanced tumor killing due to
disruption of CTLA-4 binding interaction to CD80 and CD86, which normally
downregulates T cell expansion. Ipilimumab is effective, but displays greater
toxicity compared to anti-PD-1 antibodies. However, it is suspected that the
increased toxicity may result from CTLA-4 lysosomal degradation once
ipilimumab binds. Compared to antibodies, small compounds have the advantage
of targeting intracellular CTLA-4, which comprises about ninety percent of total
CTLA-4. Therefore, targeting CTLA-4 with small compounds may be an effective
strategy to directly bind both surface and intracellular CTLA-4, whereas
antibodies can only target CTLA-4 displayed on cellular membrane. The purpose
of this study was to investigate if small compounds can directly bind CTLA-4 and
promote T cell activation. We also wanted to elucidate the mechanism of action
of these compounds. To test the small compound strategy, 10 million compounds
were screened for primary hits targeting CTLA-4 by Atomwise Incorporation using
deep learning. We inoculated MC38 colorectal cancer cells in mice that were
treated with a small compound (lead compound) and extracted the tumors. We
isolated the tumor-infiltrating lymphocytes (TILs) and measured IFN-γ levels
released by the TILs. We co-cultured extracted TILs from compound treatment or
the vehicle control (PBS) with MC38 cells with ipilimumab as a positive control.
We ran flow cytometry on Tregs from the mouse tumors. We also did lysotracker
staining on 293T cells to visualize endocytosis of CTLA-4 and localization to
lysosomes. Also, we did a western blot for CTLA-4 from Jurkat cell lysate after
incubation with either the lead compound or ipilimumab. The results showed
that ipilimumab-treated TILs from compound-treated mice release increased
levels of IFN-γ when cocultured with MC38 cells compared to the only
ipilimumab-treated TILS derived from PBS mice (Control). Flow cytometry
revealed that CD4 was downregulated in Tregs from mouse tumors that were
treated with CTLA-4 blocking compound. The Jurkat western blot showed
decreased levels of CTLA-4 when cells were treated with ipilimumab compared to
the small compound treatment. These results suggest that blocking CTLA-4 with
small compounds leads to successful binding of CLTA-4 and enhanced T cell
activation. Results also suggest that the small compounds strategy may result in
less CTLA-4 degradation compared to ipilimumab. The lysotracker experiment is
still in progress. Further experimentation will be necessary to refine the small
compound strategy to produce a safe, potent, and economic treatment targeting
CTLA-4.

RESULTS

CONCLUSIONS
CTLA-4 is an important immunoregulatory receptor because it prevents
autoimmunity, and its degradation is associated with toxicity. Currently,
targeting CTLA-4 with antibodies leads to immune toxicity. Small
compounds may be a viable alternative to using ipilimumab to target
CTLA-4 because they do not degrade their targets. Atomwise identified
72 hits after screening millions of compounds that target CTLA-4.
Compounds were confirmed to physically bind to CTLA-4 without
degrading it. In vitro testing indicated that top hits successfully prevent
tumor development in mice challenged with colon cancer cell line MC38.
TILs from A9 mice had less CD4 expression and Alphalisa experiments
showed that blocking CTLA-4 increases IFN- γ release. In conclusion,
these data suggest that small compound may be used to develop more
efficient novel therapies targeting CTLA-4 while preventing CTLA-4
degradation and immune toxicity.

Figure 1: Ipilimumab targets CTLA-4 and reduces inhibitory function. CTLA-4 and CD80/CD86 binding interaction is
disrupted and CD8+ T cell function is enhanced. Ipilimumab is thought to lead to toxicity via CTLA-4 degradation.
Small compounds may prevent toxicity because they do not degrade CTLA-4.

FUTURE DIRECTIONS
Figure 4: Flow cytometry staining for CD4. A9 compound treatment
results in less CD4 expression on TILs.
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METHODS
•Screened about 10 million compounds
•Isolated TILs from MC38 colorectal tumors grown in mice.
•CD4 flow staining on lymphocytes.
•Coculture MC38+TILs+Ipi and IFN-γ AlphaLISA.

1. Lysotracker experiment will be completed.
2. Flow data will be collected for CD25 and FOXP3.
3. Stability Experiments.

Figure 5: IFN-γ release quantification of isolated TILs from A9 treated mice and control mice.
TILs from A9 mice cocultured with MC38 and treated with Ipilimumab had highest IFN-γ
levels.
Figure 2: I) Thermal shift quantification for top hits from Atomwise screening. Compounds bind to
CTLA-4 and cause weight increase that results in delta thermal shift. II) Compounds A9, D7, and D11
bind to CTLA-4.

Figure 3: Mice were challenged with MC38 cancer cells via subcutaneous injection and were injected
every other day, for four times, with 200µg compound or PBS for control mice. MC38 tumor volume
in mice was monitored over 15-day period.

Figure 6: Western blot of lysate from Jurkat cells incubated with A9, Ipilimumab, or
PBS. Western blot quantification shows possible CTLA-4 degradation.
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